Hostname: page-component-78c5997874-v9fdk Total loading time: 0 Render date: 2024-11-10T08:48:08.477Z Has data issue: false hasContentIssue false

Lead-in placebo washout period

Published online by Cambridge University Press:  02 January 2018

J. Volavka*
Affiliation:
Nathan Kline Institute, Orangeburg, NY 10962, USA
Rights & Permissions [Opens in a new window]

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Columns
Copyright
Copyright © 1995 The Royal College of Psychiatrists 

References

Cohen, B. M., Babb, S., Campbell, A., et al (1988) Persistence of haloperidol in the brain. Archives of General Psychiatry, 45, 879880.Google Scholar
Hirsch, S. R. & Barnes, T. R. E. (1990) Testing the efficacy of new neuroleptic drugs. Methodology of the Evaluation of Psychotropic Drugs. Psychopharmacology Series 8 (eds Benkert, O., Maier, W. & Rickels, K.), p. 26. Berlin: Springer-Verlag.Google Scholar
Johnson, A. L. & Johnson, D. A. W. (1995) Peer review of “Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol”. British Journal of Psychiatry, 166, 727733.Google Scholar
Kane, J. M., Schooler, N. R., Marder, S. R., et al (1994) Methods for clinical evaluation of pharmacologic treatments of schizophrenia. Clinical Evaluation of Psychotropic Drugs. Principles and Guidelines (eds Prien, R. F. & Robinson, D. S.), p. 345. New York: Raven Press.Google Scholar
Peuskens, J. (1995) Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. British Journal of Psychiatry, 166, 712726.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.